Phenprocoumon

DRUG14 trials

Sponsors

Hamilton Health Sciences Corporation, Hamilton Health Sciences Corporation, Hamilton Health Sciences Corporation, Heart and Diabetes Center North-Rhine Westfalia, Cantonal Hospital of St. Gallen, University Hospital, Bonn

Conditions

Acute Coronary SyndromeAtherosclerosisAtrial FibrillationAtrial Fibrillation or Atrial FlutterBleedingCoronary Heart DiseaseDeep Venous ThrombosisEnd-stage Kidney Disease

Phase 1

A Study of the Effect of Vemurafenib on the Pharmacokinetics of Phenprocoumon in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy

CompletedNCT01849666

Hoffmann-La RocheMalignant Melanoma, Neoplasms

Start: 2013-09-30End: 2014-04-30Updated: 2016-11-02

Phase 2

Resolution of Left Atrial-Appendage Thrombus - Effects of Dabigatran in Patients With AF

TerminatedNCT02256683

Johannes Gutenberg University MainzAtrial Fibrillation or Atrial Flutter, Thrombosis of Left Atrial Appendage

Start: 2014-07-31End: 2018-05-31Updated: 2019-07-26

Dabigatran as an Alternative Anticoagulant in Patients With Left Ventricular Assist Device (LVAD)

TerminatedNCT02872649

Daniel Zimpfer, MDBleeding, Thrombosis

Start: 2013-01-31End: 2016-02-29Updated: 2016-08-19

Phase 3

D-Dimer Guided Oral Anticoagulant Treatment (OAT)

University Hospital, BonnDeep Venous Thrombosis

Start: 2008-02-29End: 2012-02-29Target: 300Updated: 2009-05-08

Compare Apixaban and Vitamin-K Antagonists in Patients With Atrial Fibrillation (AF) and End-Stage Kidney Disease (ESKD)

CompletedNCT02933697

Atrial Fibrillation NetworkAtrial Fibrillation, End-stage Kidney Disease

Start: 2017-06-20End: 2022-07-31Updated: 2022-09-27

The Direct Oral Anticoagulation versus Vitamin K Antagonist after Cardiac Surgery (DANCE) Trial

RecruitingCTIS2023-504504-28-00

Hamilton Health Sciences Corporation, Hamilton Health Sciences CorporationPatients with atrial fibrillation requiring anticoagulation.

Start: 2024-10-25Target: 1000Updated: 2023-12-22

Low INR to Minimize bleeding with mechanical valves Trial (LIMIT)

RecruitingCTIS2023-508532-56-00

Hamilton Health Sciences CorporationTreatment with a Vitamin K Antagonist due to having a mechanical bileaflet aortic valve replacement.

Start: 2021-10-19Target: 975Updated: 2026-01-09

Phase 4

Very Low Dose Oral Anticoagulation and Thromboembolic and Bleeding Complications

TerminatedNCT00528671

Heart and Diabetes Center North-Rhine WestfaliaMechanical Heart Valve Recipients

Start: 2006-01-31End: 2013-11-30Updated: 2013-12-11

Study to Find Out the Appropriate Initial Dose of the Anticoagulant Drug Phenprocoumon

CompletedNCT00586287

Cantonal Hospital of St. GallenAtrial Fibrillation, Hip Replacement Postoperative, Knee Replacement Postoperative +1

Start: 2007-01-31End: 2011-12-31Updated: 2012-04-02

Impact of Dabigatran and Phenprocoumon on ADP Induced Platelet Aggregation in Patients With Atrial Fibrillation

CompletedNCT01339819

Deutsches Herzzentrum MuenchenAtrial Fibrillation

Start: 2011-04-30End: 2012-09-30Updated: 2013-07-02

Impact of Dabigatran and Phenprocoumon on Clopidogrel Mediated ADP Induced Platelet Aggregation in Patients With Atrial Fibrillation

TerminatedNCT01352702

Deutsches Herzzentrum MuenchenAcute Coronary Syndrome, Atherosclerosis, Atrial Fibrillation +1

Start: 2011-05-31End: 2014-05-31Updated: 2015-02-05

Left Atrial Thrombus Reduction - Effect of Dabigatran Versus Phenprocoumon

University of UlmAtrial Fibrillation, Left Atrial Thrombosis

Start: 2015-10-31Target: 40Updated: 2015-11-13

Left Atrial Appendage CLOSURE in Patients With Atrial Fibrillation Compared to Medical Therapy

CompletedNCT03463317

Charite University, Berlin, GermanyAtrial Fibrillation

Start: 2018-02-28End: 2024-11-30Updated: 2025-12-12

Unknown Phase

Real-world Comparative Effectiveness of Stroke Prevention in Patients With Atrial Fibrillation Treated With Factor Xa Non-vitamin-K Oral Anticoagulants (NOACs) vs. Phenprocoumon

CompletedNCT03563937

BayerAtrial Fibrillation

Start: 2018-06-15End: 2019-12-10Updated: 2020-11-27

Related Papers

Health economic evaluation of left atrial appendage closure in patients with atrial fibrillation and at high risk for stroke and bleeding: a study protocol

Frontiers in Health Services2026-07-01

Left Atrial Appendage Closure or Medical Therapy in Atrial Fibrillation.

2026-03-18

Catheter-based left atrial appendage CLOSURE in patients with atrial fibrillation at high risk of stroke and bleeding as compared to best medical therapy: Rationale and design of the prospective randomized CLOSURE-AF trial.

2025-09-122 citations

A Randomized Controlled Trial Comparing Apixaban With the Vitamin K Antagonist Phenprocoumon in Patients on Chronic Hemodialysis: The AXADIA-AFNET 8 Study

Circulation2022-11-06156 citations

Should Oral Anticoagulation Be Used in ESKD Patients on Hemodialysis with Atrial Fibrillation?: PRO

Kidney3602021-04-093 citations

Should Oral Anticoagulation Be Used in ESKD Patients on Hemodialysis with Atrial Fibrillation?: CON

Kidney3602021-04-092 citations

Design and rationale of a randomised controlled trial comparing apixaban to phenprocoumon in patients with atrial fibrillation on chronic haemodialysis: the AXADIA-AFNET 8 study

BMJ Open2018-09-0137 citations

Mapping Progress in Reducing Cardiovascular Risk with Kidney Disease

Clinical Journal of the American Society of Nephrology2018-08-151 citations

Increased Thromboembolic Events With Dabigatran Compared With Vitamin K Antagonism in Left Ventricular Assist Device Patients

Circulation Heart Failure2017-05-0197 citations